Navigation Links
Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
Date:1/5/2009

LAVAL, QC, Jan. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Tuesday, January 6, 2009 at 8:30 a.m. (ET) to discuss the U.S. Food and Drug Administration's (FDA) approval of its once-daily formulation of tramadol, RYZOLT(TM). Joining Mr. James R. Howard-Tripp, President and Chief Executive Officer of Labopharm Inc., will be John H. Stewart, President and Chief Executive Officer of Purdue Pharma L.P., Labopharm's marketing partner for RYZOLT in the United States.

To access the conference call by telephone, dial 416-644-3414 or 1-800-733-7560. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Tuesday, January 13, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21293677 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health ... Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage ... is an exciting addition to our provider network, and the addition will benefit ...
(Date:1/17/2017)... Houston, TEXAS (PRWEB) , ... January 17, 2017 ... ... solution provider, today announced its partnership with Sigfox in the U.S.A. ... to cities nationwide including new offerings on large-scale environmental sensor deployments such ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, tax, ... in its IT Advisory Services practice . Rossi is the third technology consulting ... for strategic IT guidance grows, and the practice continues to expand.     , Bringing more ...
(Date:1/17/2017)... ... 17, 2017 , ... Physicians Education Review®, LCC (PER®) announces ... for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at ... Talamo, said, “We are delighted to have Sandra Lee join us as our ...
(Date:1/17/2017)... ... , ... Many people make New Year’s resolutions or renew their commitment to better health with ... for people who want to kick off 2017 with better smiles. Dr. Mondavi is offering ... special offers include: , , A new patient package for just ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , January 18, 2017 Ximbio, ... to share research resources, has opened its first North American ... ... marks an expansion for Ximbio following its launch in October ... Research Technology (CRT), the commercialization arm of the foundation Cancer ...
(Date:1/18/2017)... , Jan. 18, 2017  Astellas Pharma Inc. ... ) today announced its participation in Access Accelerated, ... non-communicable disease (NCD) prevention, diagnostics and treatment in ... other leading pharmaceutical companies and in collaboration with ... International Cancer Control (UICC), Astellas will work towards ...
(Date:1/17/2017)... -- Secretary of Health Dr. Karen Murphy ... are warning Pennsylvanians of the potentially lethal risks ... the drug in Beaver County . ... animals and is not meant for humans – it ... it," Secretary Murphy said. "It,s absolutely essential that first ...
Breaking Medicine Technology: